Table 1.
Clinicopathologic characteristics of malignant melanoma patients selected for concordance analysis
| Clinicopathologic characteristics | n (%) | concordant | non-concordant | p-value | |||
|---|---|---|---|---|---|---|---|
| Malignant melanoma patients | 111 | 108 | 3 | ||||
| Median age (range) | 62 (52–72) | 59 (51–70) | 57 (57) | .476 | |||
| ≤ 45 | 16 (14.4%) | 16 (14.8%) | 0 (0%) | .553 | |||
| 45–65 | 43 (38.7%) | 41 (38.0%) | 2 (66.7%) | ||||
| ≥ 65 | 52 (46.8%) | 51 (42.7%) | 1 (33.3%) | ||||
| ECOG performance status, n (%) | .011* | ||||||
| ECOG 0 | 93 (83.8%) | 91 (84.3%) | 2 (66.7%) | ||||
| ECOG 1 | 9 (8.1%) | 9 (8.3%) | 0 (0%) | ||||
| ECOG 2 | 6 (5.4%) | 6 (5.6%) | 0 (0%) | ||||
| ECOG 3 | 3 (2.7%) | 2 (1.9%) | 1 (33.3%) | ||||
| Status at initial diagnosis, n (%) | <.001** | ||||||
| Localized melanoma | 99 (89.2%) | 98 (90.7%) | 1 (33.3%) | ||||
| Regional lymph node metastases | 7 (6.3%) | 5 (4.6%) | 2 (66.7%) | ||||
| Metastatic melanoma | 5 (4.5%) | 5 (4.6%) | 0 (0%) | ||||
| Melanoma stage, n (%) | .871 | ||||||
| I | 3 (2.7%) | 3 (2.8%) | 0 (0%) | ||||
| II | 19 (17.1%) | 18 (16.7%) | 1 (33.3%) | ||||
| III | 85 (76.6%) | 83 (76.9%) | 2 (66.7%) | ||||
| IV | 4 (3.6%) | 4 (3.7%) | 0 (0%) | ||||
| Histogenetic type, n (%) | .906 | ||||||
| Superficial spreading melanoma | 26 (23.4%) | 26 (24.1%) | 0 (0%) | ||||
| Nodular melanoma | 47 (42.3%) | 45 (41.7%) | 2 (66.7%) | ||||
| Lentigo maligna melanoma | 1 (0.9%) | 1 (0.9%) | 0 (0%) | ||||
| Acral lentiginous melanoma | 5 (4.5%) | 5 (4.6%) | 0 (0%) | ||||
| Amelanotic melanoma | 5 (4.5%) | 5 (4.6%) | 0 (0%) | ||||
| NA, other type | 27 (24.3%) | 26 (24.1%) | 1 (33.3%) | ||||
| Sentinel lymph node biopsy, n (%) | .001** | ||||||
| Positive | 76 (68.5%) | 76 (70.4%) | 0 (0%) | ||||
| Negative | 14 (12.6%) | 14 (13.0%) | 0 (0%) | ||||
| NA | 21 (18.9%) | 18 (16.7%) | 3 (100%) | ||||
| Gene mutation status, n (%) | .943 | ||||||
| BRAF | 9 (8.1%) | 9 (8.3%) | 0 (0%) | ||||
| NRAS | 6 (5.4%) | 6 (5.6%) | 0 (0%) | ||||
| cKIT | 1 (0.9%) | 1 (0.9%) | 0 (0%) | ||||
| wild type | 6 (5.4%) | 6 (5.6%) | 0 (0%) | ||||
| NA | 89 (80.2%) | 86 (79.6%) | 3(100%) | ||||
| Resection | .002** | ||||||
| Performed | 10 (9.0%) | 8 (7.4%) | 2 (66.7%) | ||||
| Not performed | 2 (1.8%) | 2 (1.9%) | 0 (0%) | ||||
| NA | 99 (89.2%) | 98 (90.7%) | 1 (33.3%) | ||||
| Postresection residual cancer status, n (%) | <.001** | ||||||
| R0 | 8 (7.2%) | 7 (6.5%) | 1 (33.3%) | ||||
| R1 | 2 (1.8%) | 1 (0.9%) | 1 (33.3%) | ||||
| NA | 101 (91.0%) | 100 (92.6%) | 1 (33.3%) | ||||
| Complete lymph node dissection, n (%) | >.999 | ||||||
| Performed | 1 (0.9%) | 1 (0.9%) | 0 (0%) | ||||
| Not performed | 110 (99.1%) | 107 (99.1%) | 3 (100%) | ||||
Values are presented as median or number (%). Concordant cases include “concordant” cases and cases defined as "correct alternative recommendation” cases
ECOG Eastern Cooperative Oncology Group; NA not available (not relevant or” pending” for EO‘s query); R0 no residual cancer; R1 macroscopic residual cancer removed, while margins remain positive for microscopic residual cancer. Bold type numbers indicate statistical significance
**denotes that the p-value is significant at 1% level, and * that the p-value is significant at 5% level